Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/1924

Titlec-myc, not her-2/ neu, can predict the prognosis of breast cancer patients : how novel, how accurate, and how significant?
Author(s)Schmitt, Fernando C.
Reis Filho, Jorge S.
Keywordsc-erbB-2
Prognosis
c-myc
her-2/neu
Oncogene
Polymerase chain reaction
Issue dateApr-2003
PublisherBioMed Central
JournalBreast Cancer Research
Citation"Breast Cancer Research". ISSN 1465-5411. 5 (2003) 188-191.
Abstract(s)The predictive and prognostic implication of oncogene amplification in breast cancer has received great attention in the past two decades. her-2/neu and c-myc are two oncogenes that are frequently amplified and overexpressed in breast carcinomas. Despite the extensive data on these oncogenes, their prognostic and predictive impact on breast cancer patients remains controversial. Schlotter and colleagues have recently suggested that c-myc, and not her-2/neu, could predict the recurrence and mortality of patients with node-negative breast carcinomas. Regardless of the promising results, caution should be exercised in the interpretation of data from studies assessing gene amplification without in situ analysis. We address the novelty, accuracy and clinical significance of the study by Schlotter and colleagues.
TypeArticle
URIhttp://hdl.handle.net/1822/1924
DOI10.1186/bcr606
ISSN1465-5411
1465-542X
Peer-Reviewedyes
AccessOpen access
Appears in Collections:ICVS - Artigos em Revistas Internacionais com Referee

Files in This Item:
File Description SizeFormat 
Breast Cancer Res - 2003.pdf47,73 kBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID